Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
News|Videos|January 19, 2026
Get Ready for '26: What You Need to Know About the Pharma Market
A look back, a look ahead. In this webinar, Luke Greenwalt, MBA, of IQVIA and Jeff Casberg, RPh, M.S. of IPD Analytics will be discussing the MFN policy, the direct-to-consumer channel, the GLP-1 demand, the drug pipeline and more.
Advertisement
Advertisement
Related to this article
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
Why consumers still can’t comparison shop for medication
3
The hidden costs of routine radiology and how they can be addressed
4
When the referral isn't the finish line: Making SDOH programs actually close care gaps
5